BioSpace News Archive

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors.

Onkos Surgical, Inc., an innovator in the field of musculoskeletal oncology and personalized orthopaedics, continues to deliver on its promise of commercializing innovative solutions with the launch of the new ELEOS Proximal Tibia with BioGrip technology.

OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective December 18, 2020.

Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA)for XEOMIN® (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or droolin

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced the pre-print publication of a manuscript titled “Apoptotic cells for therapeutic use in cytokine storm associated with sepsis,” on medRxiv.org.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s interim data report for part 2b of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart Live! webcast. They

Aileron’s 2021 strategic priorities aim to advance its vision to bring chemoprotection to all patients with p53-mutant cancers regardless of cancer indication or chemotherapy. Key anticipated milestones include: -- Initiate Phase 1b randomized, placebo-controlled clinical trial of novel chemoprotective agent ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line carboplatin doublet chemotherapy in second quarter 2021

Longevity Acquisition Corporation (NASDAQ: LOAC) (the “Company”), a publicly-traded special purpose acquisition company, announced today that on December 18, 2020 , 4D pharma plc (AIM: DDDD) (“4D pharma”), a pharmaceutical company leading the development of Live Biotherapeutic products (“LBPs”) - a novel class of drug derived from the

Faricimab given every eight weeks and at personalized dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies

Vicore Pharma Holding AB, a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, reports an expanded data analysis to follow up the encouraging top line data from the ATTRACT study reported on December 8, 2020.